Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TXN | P10599 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9559723 | 1.00 | BCL2L1 (0.42) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL28875378 | 0.97 | BCL2L1 (0.41) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL27283535 | 0.97 | BCL2L1 (0.41) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL28042450 | 0.90 | BCL2L1 (0.37) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL28256971 | 0.84 | CA1 (0.42) | NPC1RAB9ACA1CA2CA7 | |
| SCHEMBL208526 | 0.84 | ALDH1A1 (0.35) | — | |
| SCHEMBL17200849 | 0.84 | ALDH1A1 (0.35) | — | |
| SCHEMBL2120 | 0.81 | — | — | |
| Water SCHEMBL28104228 | 0.81 | — | — | |
| SCHEMBL10300262 | 0.80 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| CN-117396465-A | Novel oxazole derivative for preventing or treating allergic diseases and pharmaceutical composition containing the same | 阿斯克里斯有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-116987100-A | Isothiazole bithiazolopyrimidine amine derivatives, and preparation method and application thereof | 南开大学 | 2023-11-03 | — | — | CN | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| CN-109153682-B | Novel pyrazine compounds with oxygen, sulfur and nitrogen linkers for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | claimed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | claimed |
| EP-3720858-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| CN-111699189-A | Modulators of beta-3 adrenergic receptors useful for the treatment or prevention of heart failure and disorders associated therewith | 艾尼纳制药公司 | 2020-09-22 | — | — | CN | claimed |
| WO-2019113359-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| WO-2001064644-A1 | DICHLOROPYRIDYL- AND DICHLOROISOTHIAZOLYL-THIOCARBOXAMIDES AND THEIR USE AS MICROBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 2001-09-07 | — | — | WO | claimed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-6107337-A | ANTIARTHRITIC AGENTS; ANTICARCINOGENIC AGENTS | PFIZER INC. (US) | 2000-08-22 | — | — | US | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| EP-0895988-A1 | Arylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0673374-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | claimed |
| WO-1994013657-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | claimed |
| US-4096338-A | ANTIPHLOGISTIC | NISSHIN FLOUR MILLING CO., LTD. (JA) | 1978-06-20 | — | — | US | claimed |
| US-4042617-A | FROM A GLYCIDIC ACID ESTER | NISSHIN FLOUR MILLING CO., LTD. (JA) | 1977-08-16 | — | — | US | claimed |
| US-4016196-A | HEATING GLYCIDIC ESTERS | NISSHIN FLOUR MILLING CO., LTD. (JA) | 1977-04-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | BCL2L1 2892/4885BAD 912/4885MAOB 462/4885 |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | BCL2L1 2864/4885BAD 967/4885MAOB 434/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | BCL2L1 2864/4885BAD 967/4885MAOB 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.